Physician profile
Kunal Agarwal
NPI 1932497773
$153,310.68
in general payments reported to CMS, 2019-2025
60 companies · $39K in 2025
The $39K reported for 2025 was more than what 94% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $4,080 · 2021: $18K · 2022: $11K · 2023: $46K · 2024: $35K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Honoraria: $27K · Consulting Fee: $14K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Travel and Lodging: $8,285 · Education: $35.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,590.00 |
| Honoraria | $26,600.00 |
| Consulting Fee | $14,400.00 |
| Food and Beverage | $13,411.72 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,275.00 |
| Travel and Lodging | $8,284.90 |
| Education | $35.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $34,701.12 | 2022-2024 | Quviviq |
| Inspire Medical Systems, INC. | $26,495.20 | 2020-2025 | Inspire |
| Axsome Therapeutics, INC. | $25,573.87 | 2022-2025 | Sunosi, Auvelity |
| Zoll Respicardia, INC. | $25,315.81 | 2021-2025 | Remede System |
| Jazz Pharmaceuticals INC. | $19,379.37 | 2019-2025 | Xywav |
| Eisai INC. | $9,603.68 | 2020-2022 | |
| Harmony Biosciences LLC | $2,510.89 | 2020-2025 | Wakix |
| Fisher & Paykel Healthcare INC | $1,812.43 | 2022-2024 | Fisher & Paykel Healthcare |
| Novo Nordisk INC | $1,728.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $1,209.05 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $443.87 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Avadel Cns Pharmaceuticals, LLC | $421.51 | 2023-2025 | Lumryz |
| Pfizer INC. | $414.66 | 2019-2025 | |
| Amgen INC. | $406.83 | 2019-2025 | Repatha |
| Lilly USA, LLC | $368.44 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.